FDA Approves New Melanoma Drug


March 28, 2011

LA Times

Lynn Schuchter, MD, chief of the division of Hematology-Oncology, is quoted in an article in the Los Angeles Times and the Chicago Tribune about the FDA approval of a new metastatic melanoma drug, Yervoy (known generically as ipilimumab). Studies have shown that patients treated with Yervoy, or with Yervoy and an experimental tumor vaccine, lived 10 months, compared with 6.5 months for patients who received only the vaccine. The extension of life is significant because the study looked at patients who had already received other treatments for late-stage melanoma, Schuchter said. The real promise of Yervoy is that some patients who receive the drug live much longer than 10 months and may be cured of the disease, she said... Read More

Communications placement